ANAPTYSBIO INC. - COMMON STOCK

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 мар 2024 15:15:00 Источник Nasdaq GlobeNewswire

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

29 фев 2024 08:15:00 Источник Nasdaq GlobeNewswire

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

31 янв 2024 08:15:00 Источник Nasdaq GlobeNewswire

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

27 ноя 2023 15:15:00 Источник Nasdaq GlobeNewswire

Anaptys Named a BioSpace 2024 Best Places to Work Winner

07 ноя 2023 15:15:00 Источник Nasdaq GlobeNewswire

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

02 ноя 2023 15:15:00 Источник Nasdaq GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

01 ноя 2023 08:15:00 Источник Nasdaq GlobeNewswire

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

11 окт 2023 08:15:00 Источник Nasdaq GlobeNewswire

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

09 окт 2023 07:15:00 Источник Nasdaq GlobeNewswire

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

09 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

18 сен 2023 15:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

12 сен 2023 08:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

07 авг 2023 15:15:09 Источник Nasdaq GlobeNewswire

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

31 июл 2023 12:34:57 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Participation in Upcoming Investor Conferences

30 май 2023 15:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

11 май 2023 15:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

02 май 2023 08:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

06 апр 2023 15:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

27 мар 2023 17:50:32 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

01 мар 2023 15:05:01 Источник Nasdaq GlobeNewswire